The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents, 2005-2012
Open accessAbstract
IMPORTANCE: Many patients and physicians assume that the safety and effectiveness of newly approved therapeutic agents is well understood; however, the strength of the clinical trial evidence supporting approval decisions by the US Food and Drug Administration (FDA) has not been evaluated. OBJECTIVES: To characterize pivotal efficacy trials (clinical trials that serve as the basis of FDA approval) for newly approved novel therapeutic agents. DESIGN AND SETTING: Cross-sectional analysis using publicly available FDA documents for all novel therapeutic agents approved between 2005 and 2012. MAIN OUTCOMES AND MEASURES: Pivotal efficacy trials were classified according to the following design features: randomization, blinding, comparator, and trial end point. Surrogate outcomes were defined as any end point using a biomarker expected to predict clinical benefit. The number of patients, trial duration, and trial completion rates were also determined. RESULTS: Between 2005 and 2012, the FDA approved 188 novel therapeutic agents for 206 indications on the basis of 448 pivotal efficacy trials. The median number of pivotal trials per indication was 2 (interquartile range, 1-2.5), although 74 indications (36.8%) were approved on the basis of a single pivotal trial. Nearly all trials were randomized (89.3% [95% CI, 86.4%-92.2%]), double-blinded (79.5% [95% CI, 75.7%-83.2%]), and used either an active or placebo comparator (87.1% [95% CI, 83.9%-90.2%]). The median number of patients enrolled per indication among all pivotal trials was 760 (interquartile range, 270-1550). At least 1 pivotal trial with a duration of 6 months or greater supported the approval of 68 indications (33.8% [95% CI, 27.2%-40.4%]). Pivotal trials using surrogate end points as their primary outcome formed the exclusive basis of approval for 91 indications (45.3% [95% CI, 38.3%-52.2%]), clinical outcomes for 67 (33.3% [95% CI, 26.8%-39.9%]), and clinical scales for 36 (17.9% [95% CI, 12.6%-23.3%]). Trial features differed by therapeutic and indication characteristics, such as therapeutic area, expected length of treatment, orphan status, and accelerated approval. CONCLUSIONS AND RELEVANCE: The quality of clinical trial evidence used by the FDA as the basis for recent approvals of novel therapeutic agents varied widely across indications. This variation has important implications for patients and physicians as they make decisions about the use of newly approved therapeutic agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs
Concato, J., Shah, N., & Horwitz, R. I. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006223422507 · Cited by 3,563
Self-citationSurrogate End Points in Clinical Trials: Are We Being Misled?
Fleming, T. R., & DeMets, D. L. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-7-199610010-00011 · Cited by 1,651
Smith, G. C. S., & Pell, J. P. (2003) · BMJ · doi:10.1136/bmj.327.7429.1459 · Cited by 1,157
Clement, F. M., Harris, A., Li, J. J., Yong, K., Lee, K. M., & Manns, B. J. (2009) · JAMA · doi:10.1001/jama.2009.1409 · Cited by 343
Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease
(2010) · National Academies Press eBooks · doi:10.17226/12869 · Cited by 276
Characteristics of Clinical Trials to Support Approval of Orphan vs Nonorphan Drugs for Cancer
Kesselheim, A. S. (2011) · JAMA · doi:10.1001/jama.2011.769 · Cited by 230
Strength of Study Evidence Examined by the FDA in Premarket Approval of Cardiovascular Devices
Dhruva, S. S. (2009) · JAMA · doi:10.1001/jama.2009.1899 · Cited by 198
Equipoise and the Dilemma of Randomized Clinical Trials
Miller, F. G., & Joffe, S. (2011) · New England Journal of Medicine · doi:10.1056/nejmsb1011301 · Cited by 189
Regulatory Review of Novel Therapeutics — Comparison of Three Regulatory Agencies
Downing, N. S., Aminawung, J. A., Shah, N. D., Braunstein, J. B., Krumholz, H. M., & Ross, J. S. (2012) · New England Journal of Medicine · doi:10.1056/nejmsa1200223 · Cited by 176
Self-citationChen, D. T., Wynia, M. K., Moloney, R., & Alexander, G. C. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1825 · Cited by 97
Cited by
FDA Approval and Regulation of Pharmaceuticals, 1983-2018
Darrow, J. J., Avorn, J., & Kesselheim, A. S. (2020) · JAMA · doi:10.1001/jama.2019.20288 · Cited by 377
Moore, T. J., Zhang, H., Anderson, G., & Alexander, G. C. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.3931 · Cited by 356
Downing, N. S., Shah, N. D., Aminawung, J. A., Pease, A. M., Zeitoun, J.-D., Krumholz, H. M., & Ross, J. S. (2017) · JAMA · doi:10.1001/jama.2017.5150 · Cited by 324
Self-citationWong, J., Motulsky, A., Abrahamowicz, M., Eguale, T., Buckeridge, D. L., & Tamblyn, R. (2017) · BMJ · doi:10.1136/bmj.j603 · Cited by 221
Cardiovascular Drug Development
Fordyce, C. B., Roe, M. T., Ahmad, T., Libby, P., Borer, J. S., Hiatt, W. R., Bristow, M. R., Packer, M., Wasserman, S. M., Braunstein, N., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.03.016 · Cited by 202
Metadata
- Authors
- Downing, N. S., Aminawung, J. A., Shah, N. D., Krumholz, H. M., & Ross, J. S.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2014-01-22
- Volume
- 311
- Issue
- 4
- Pages
- 368
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2140922502
- Cited by
- 407
- References
- 16
- FWCI
- 47.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents, 2005-2012. https://app.cochat.ai/papers/10.1001/jama.2013.282034
- The paper
- Downing, N. S., Aminawung, J. A., Shah, N. D., Krumholz, H. M., & Ross, J. S. (2014). Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents, 2005-2012. JAMA. https://doi.org/10.1001/jama.2013.282034
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.